Madrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.
Sanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m.
Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.